riliprubart

News

Sanofi's neurology pipeline has had a hole blown in it after a phase 3 trial of riliprubart in rare disease CIDP was stopped for futility.

Oncology

Kate Estep discusses Flatiron’s AI-powered oncology intelligence platform, Telescope, and how AI tools are changing research decisions.

Sales & Marketing

Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.